An autopsy case report of fulminant myocarditis: Following mRNA COVID-19 vaccination

Naoki Hoshino; Masanobu Yanase; Taisuke Ichiyasu; Kazuhiko Kuwahara; Hideki Kawai; Takashi Muramatsu; Hideki Ishii; Tetsuya Tsukamoto; Shin ichiro Morimoto; Hideo Izawa

doi:10.1016/j.jccase.2022.06.006

An autopsy case report of fulminant myocarditis: Following mRNA COVID-19 vaccination

Naoki Hoshino
, Masanobu Yanase
, Taisuke Ichiyasu
, Kazuhiko Kuwahara
, Hideki Kawai
, Takashi Muramatsu
, Hideki Ishii
, Tetsuya Tsukamoto
, Shin ichiro Morimoto
, Hideo Izawa

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

There have been few case reports on fatal outcomes in patients with acute myocarditis after mRNA coronavirus disease 2019 (COVID-19) vaccination. In most cases of myocarditis after mRNA COVID-19 vaccination, the myocarditis is mild, and the prognosis is good. Here we report an autopsy case of fulminant myocarditis following mRNA COVID-19 vaccination. Learning objective: The global distribution of the mRNA coronavirus disease 2019 vaccine requires consideration of appropriate treatment for postvaccination myocarditis. Eosinophil-mediated immunological injury to cardiomyocytes can be involved in the cause of fulminant inflammation from the pathological findings of postvaccination myocarditis.

Original language	English
Pages (from-to)	391-394
Number of pages	4
Journal	Journal of Cardiology Cases
Volume	26
Issue number	6
DOIs	https://doi.org/10.1016/j.jccase.2022.06.006
Publication status	Published - 12-2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jccase.2022.06.006

Cite this

@article{14d4e01f76bb404baa71b8ad5f39a5e7,

title = "An autopsy case report of fulminant myocarditis: Following mRNA COVID-19 vaccination",

abstract = "There have been few case reports on fatal outcomes in patients with acute myocarditis after mRNA coronavirus disease 2019 (COVID-19) vaccination. In most cases of myocarditis after mRNA COVID-19 vaccination, the myocarditis is mild, and the prognosis is good. Here we report an autopsy case of fulminant myocarditis following mRNA COVID-19 vaccination. Learning objective: The global distribution of the mRNA coronavirus disease 2019 vaccine requires consideration of appropriate treatment for postvaccination myocarditis. Eosinophil-mediated immunological injury to cardiomyocytes can be involved in the cause of fulminant inflammation from the pathological findings of postvaccination myocarditis.",

keywords = "Autopsy, Coronavirus disease 2019, Eosinophilic myocarditis, Myocarditis, Vaccination, mRNA",

author = "Naoki Hoshino and Masanobu Yanase and Taisuke Ichiyasu and Kazuhiko Kuwahara and Hideki Kawai and Takashi Muramatsu and Hideki Ishii and Tetsuya Tsukamoto and Morimoto, \{Shin ichiro\} and Hideo Izawa",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = dec,

doi = "10.1016/j.jccase.2022.06.006",

language = "English",

volume = "26",

pages = "391--394",

journal = "Journal of Cardiology Cases",

issn = "1878-5409",

publisher = "Elsevier Ltd",

number = "6",

}

TY - JOUR

T1 - An autopsy case report of fulminant myocarditis

T2 - Following mRNA COVID-19 vaccination

AU - Hoshino, Naoki

AU - Yanase, Masanobu

AU - Ichiyasu, Taisuke

AU - Kuwahara, Kazuhiko

AU - Kawai, Hideki

AU - Muramatsu, Takashi

AU - Ishii, Hideki

AU - Tsukamoto, Tetsuya

AU - Morimoto, Shin ichiro

AU - Izawa, Hideo

PY - 2022/12

Y1 - 2022/12

N2 - There have been few case reports on fatal outcomes in patients with acute myocarditis after mRNA coronavirus disease 2019 (COVID-19) vaccination. In most cases of myocarditis after mRNA COVID-19 vaccination, the myocarditis is mild, and the prognosis is good. Here we report an autopsy case of fulminant myocarditis following mRNA COVID-19 vaccination. Learning objective: The global distribution of the mRNA coronavirus disease 2019 vaccine requires consideration of appropriate treatment for postvaccination myocarditis. Eosinophil-mediated immunological injury to cardiomyocytes can be involved in the cause of fulminant inflammation from the pathological findings of postvaccination myocarditis.

AB - There have been few case reports on fatal outcomes in patients with acute myocarditis after mRNA coronavirus disease 2019 (COVID-19) vaccination. In most cases of myocarditis after mRNA COVID-19 vaccination, the myocarditis is mild, and the prognosis is good. Here we report an autopsy case of fulminant myocarditis following mRNA COVID-19 vaccination. Learning objective: The global distribution of the mRNA coronavirus disease 2019 vaccine requires consideration of appropriate treatment for postvaccination myocarditis. Eosinophil-mediated immunological injury to cardiomyocytes can be involved in the cause of fulminant inflammation from the pathological findings of postvaccination myocarditis.

KW - Autopsy

KW - Coronavirus disease 2019

KW - Eosinophilic myocarditis

KW - Myocarditis

KW - Vaccination

KW - mRNA

UR - https://www.scopus.com/pages/publications/85134796480

UR - https://www.scopus.com/pages/publications/85134796480#tab=citedBy

U2 - 10.1016/j.jccase.2022.06.006

DO - 10.1016/j.jccase.2022.06.006

M3 - Article

AN - SCOPUS:85134796480

SN - 1878-5409

VL - 26

SP - 391

EP - 394

JO - Journal of Cardiology Cases

JF - Journal of Cardiology Cases

IS - 6

ER -

An autopsy case report of fulminant myocarditis: Following mRNA COVID-19 vaccination

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this